Search
01/03/2026
Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.
Hoffman-Censits, J, Tsiatas, M, Chang, PMH, Kim, M, Zagouri, F, Shin, SJ, Kim, SH, Su, HYL, Arija, JAA, Maroto-Rey, JP, Antonuzzo, L, Maruzzo, M, Tambaro, R, Blais, N, Rottey, S, Gakis, G, Schneider, A, Tyroller, K, Jacob, N, Valderrama, BP. Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.739. PMID:. IF:41.900(Q1/1D).
01/03/2026
Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.
Villarrubia, JE, Fita, MJJ, de Liaño, AG, Cerrillomd, JM, Cruz, P, Anguera, G, Puente, J, Torras, OR, Navarro-Gorro, N, Pinto, A, Ruiz, SG, Cacho, D, Maeso, IG, González, NS, Lainez, N, Herranz, UA, Carrera-Lasfuentes, P, Climent, MA, Macías, NR, Castellano, D. Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.700. PMID:. IF:41.900(Q1/1D).
01/03/2026
SEOM-AEEMT consensus on occupational cancer and cancer-associated disability
Mezquita, L, Vicente-Herrero, MT, Cruz, P, de la Torre, MVRI, Hidalgo-Coloma, J, Garcia, LC, Gallego, O, Calvo, A, Martinez, K, Perez-Altozano, J, Molina, R, Garcia-Pardo, M, Gutierrez-Sainz, L, Moreno-Atahonero, E, Ore-Arce, M, Serrano, C, Terradillos-Garcia, MJ, Valero, MR, Reinoso-Barbero, L, Rodriguez, CA, Calvo-Cerrada, B. SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. Clinical & Translational Oncology. 2026; 28(3)DOI:10.1007/s12094-025-04037-2. PMID:40956506. IF:2.500(Q3/6D).
01/03/2026
REAL-WORLD EVIDENCE FOR FIXED TRIPLE THERAPY WITH BECLOMETHASONE/FORMOTEROL/GLYCOPYRRONIUM IN ASTHMA PATIENTS WITH CONCOMITANT COPD: SIX-MONTH RESULTS OF TRIMAXIMIZE
Harniman, K, Gessner, C, Bogoevska, V, Russell, R, Ulrik, CS, Pohl, W, Plaza, V, Bourdin, A, Fritz, C, Hahn, A, Trinkmann, F. REAL-WORLD EVIDENCE FOR FIXED TRIPLE THERAPY WITH BECLOMETHASONE/FORMOTEROL/GLYCOPYRRONIUM IN ASTHMA PATIENTS WITH CONCOMITANT COPD: SIX-MONTH RESULTS OF TRIMAXIMIZE. INTERNAL MEDICINE JOURNAL. 2026; 56DOI:. PMID:. IF:1.500(Q2/5D).
01/03/2026
SEPAR Recommendations on Vaccination for Chronic Respiratory Patients
de Miguel-Díez, J, Torres-Castro, R, Herrero, FS, Villanueva, RM, Gómez, BS, Fernández, SQ, Rojo, RP, Cuesta, VMM, Castillo, ME, Fernández, LS, Martínez, MMC, Mediano, O, García-Ortega, A, Rivero, JLG, de la Rosa-Carrillo, D. SEPAR Recommendations on Vaccination for Chronic Respiratory Patients. ARCHIVOS DE BRONCONEUMOLOGIA. 2026; 62(3)DOI:10.1016/j.arbres.2025.06.005. PMID:40592680. IF:9.200(Q1/1D).
01/03/2026
Interpretable Artificial Intelligence Model for the Automatic Identification of Botryoid Neutrophils
Merino, A, Barrera, K, Verdú, G, San José, P, Vallbé, M, Molina, A, Rodellar, J. Interpretable Artificial Intelligence Model for the Automatic Identification of Botryoid Neutrophils. International Journal of Laboratory Hematology. 2026; 48DOI:. PMID:. IF:2.300(Q2/5D).